Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

JW Therapeutics to Develop Two Additional 2seventy Cell Therapies in China

publication date: Sep 14, 2023

Shanghai JW Therapeutics will add two additional candidates for China to its T cell-based therapeutics collaboration with Boston’s 2seventy bio: a T-cell receptor molecule for solid tumors and a CAR T candidate for autoimmune diseases. The collaboration, announced last year, was set up to advance 2seventy products into clinical trials quickly. One of the two original products, a MAGE-A4 solid tumor program, is expected to start an investigator study later this year, which is faster than expected. JW was formed by Wuxi Apptec and Seattle’s Juno Therapeutics to bring cell therapies to China. More details....

Stock Symbols: (HK: 2126) (Nasdaq: TSVT)

Share this with colleagues: